The cost-effectiveness of periodic safety update reports for biologicals in Europe

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 5, 2013, Pages 433-442

  Bouvy, J C ^a,b   Ebbers, H C ^a   Schellekens, H ^a,c   Koopmanschap, M A ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDEMA; EUROPE; OFF LABEL DRUG USE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOLOGICAL AGENTS; BONE MORPHOGENETIC PROTEIN 2; BOTULINUM TOXINS; COST-BENEFIT ANALYSIS; EUROPE; EUROPEAN UNION; HUMANS; LEGISLATION, DRUG; MARKOV CHAINS; OFF-LABEL USE; PHARMACOVIGILANCE; QUALITY-ADJUSTED LIFE YEARS;

EID: 84876685477     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.13     Document Type: Article

References (36)

1. Stricker, B.H. & Psaty, B.M. Detection, verifcation, and quantifcation of adverse drug reactions. BMJ 329, 44-47 (2004).
2. Wise, L., Parkinson, J., Raine, J. & Breckenridge, A. New approaches to drug safety: a pharmacovigilance tool kit. Nat. Rev. Drug Discov. 8, 779-782 (2009).
3. Klepper, M.J. The periodic safety update report as a pharmacovigilance tool. Drug Saf. 27, 569-578 (2004).
4. European Medicines Agency. Volume 9A of The Rules Governing Medicinal Products in the European Union 〈http://www.ec.europa.eu/enterprise/ pharmaceuticals/eudralex/vol-9/pdf/vol9a-09-2008.pdf〉 (2008).
5. Bouvy, J.C., Koopmanschap, M.A., Shah, R.R. & Schellekens, H. The cost-efectiveness of drug regulation: the example of thorough QT/QTc studies. Clin. Pharmacol. Ther. 91, 281-288 (2012).
6. Reed, S.D., Anstrom, K.J., Seils, D.M., Calif, R.M. & Schulman, K.A. Use of larger versus smaller drug-safety databases before regulatory approval: the trade-ofs. Health Af. (Millwood). 27, w360-w370 (2008).
7. Bouvy, J.C., Koopmanschap, M.A. & Schellekens, H. Value for money of drug regulation. Expert Rev. Pharmacoecon. Outcomes Res. 12, 247-249 (2012).
8. Ridley, D.B., Kramer, J.M., Tilson, H.H., Grabowski, H.G. & Schulman, K.A. Spending on postapproval drug safety. Health Af. (Millwood). 25, 429-436 (2006).
9. European Commission. Proposal for a regulation amending, as regards pharmacovigilance of medicinal products for human use. Regulation (EC) No 726/2004. Impact Assessment 〈http://www.ec.europa.eu/health/fles/pharmacos/ pharmpack-12-2008/pharmacovigilance-ia-vol1-en.pdf〉 2008).
10. Ebbers, H.C., Mantel-Teeuwisse, A.K., Sayed-Tabatabaei, F.A., Moors, E.H., Schellekens, H. & Leufkens, H.G. The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals. Eur. J. Clin. Pharmacol. 69, 217-226 (2013).
11. Ebbers, H.C., Mantel-Teeuwisse, A.K., Moors, E.H., Sayed Tabatabaei, F.A., Schellekens, H. & Leufkens, H.G. A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals. Drug Saf. 35, 417-427 (2012).
12. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP)4 Module IX-Signal management (draft). 〈http://www.ema.europa.eu/docs/ en-GB/document-library/Scientifc-guideline/2012/06/WC500129138.pdf〉 (2012).
13. Giezen, T.J., Mantel-Teeuwisse, A.K., Meyboom, R.H., Straus, S.M., Leufkens, H.G. & Egberts, T.C. Mapping the safety profle of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf. 33, 865-878 (2010).
14. Piening, S. et al. Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands. Clin. Pharmacol. Ther. 91, 838-845 (2012).
15. Piening, S. et al. Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf. 35, 373-385 (2012).
16. Malgarini, R.B. & Pimpinella, G. Thrombotic thrombocytopenic purpura induced by ticlopidine: the power of "dear health professional" letters. Ann. Pharmacother. 34, 404-405 (2000).
17. Motola, D. et al. Infuence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. Drug Saf. 31, 609-616 (2008).
18. Farmer, R.D., Williams, T.J., Simpson, E.L. & Nightingale, A.L. Efect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database. BMJ 321, 477-479 (2000).
19. Wheeler, B.W., Metcalfe, C., Gunnell, D., Stephens, P. & Martin, R.M. Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study. Br. J. Clin. Pharmacol. 68, 752-764 (2009).
20. Reed, S.D., Calif, R.M. & Schulman, K.A. How changes in drug-safety regulations afect the way drug and biotech companies invest in innovation. Health Af. (Millwood). 25, 1309-1317 (2006).
21. Scannell, J.W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efciency. Nat. Rev. Drug Discov. 11, 191-200 (2012).
22. Paul, S.M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
23. Carragee, E.J., Ghanayem, A.J., Weiner, B.K., Rothman, D.J. & Bono, C.M. A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors. Spine J. 11, 463-468 (2011).
24. Kessler, K.R., Skutta, M. & Benecke, R. Long-term treatment of cervical dystonia with botulinum toxin A: efcacy, safety, and antibody frequency. German Dystonia Study Group. J. Neurol. 246, 265-274 (1999).
25. European Commission. Introduction of fees to be charged by the EMA for pharmacovigilance: Concept paper submitted for public consultation 〈http://www.ec.europa.eu/health/fles/pharmacovigilance/2012-06-concept- paper-en.pdf〉 (2012).
26. Eurostat. Harmonised indices for consumer prices (HICP). 〈http://www.epp. eurostat.ec.europa.eu/tgm/table.do?tab=table&language= en&pcode= tec00118&tableSelection=1&footnotes=yes&labeling= labels&plugin=1〉 2012).
27. Mauskopf, J.A. & French, M.T. Estimating the value of avoiding morbidity and mortality from foodborne illnesses. Risk Anal. 11, 619-631 (1991).
28. Tan, S.S., Bouwmans, C.A., Rutten, F.F. & Hakkaart-van Roijen, L. Update of the Dutch Manual for Costing in Economic Evaluations. Int. J. Technol. Assess. Health Care 28, 152-158 (2012).
29. National Medical Registration (LMR). Hospital admissions the Netherlands 〈http://www.kiwaprismant.nl/prismant/expertise.aspx?id=13450〉 (2012).
30. Williams, B.J. et al.; Scoliosis Research Society Morbidity and Mortality Committee. Does bone morphogenetic protein increase the incidence of perioperative complications in spinal fusion? A comparison of 55, 862 cases of spinal fusion with and without bone morphogenetic protein. Spine 36, 1685-1691 (2011).
31. Cahill, K.S., Chi, J.H., Day, A. & Claus, E.B. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 302, 58-66 (2009).
32. Martikainen, K.K., Luukkaala, T.H. & Marttila, R.J. Working capacity and cervical dystonia. Parkinsonism Relat. Disord. 16, 215-217 (2010).
33. Glassman, S.D., Howard, J., Dimar, J., Sweet, A., Wilson, G. & Carreon, L. Complications with recombinant human bone morphogenic protein-2 in posterolateral spine fusion: a consecutive series of 1037 cases. Spine 36, 1849-1854 (2011).
34. Hilker, R., Schischniaschvili, M., Ghaemi, M., Jacobs, A. & Rudolf, J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J. Neurol. Neurosurg. Psychiatr. 71, 193-199 (2001).
35. Dutch Healthcare Authority. Diagnosis-related group (DBC) tarifs for the Netherlands 〈http://www.dbc-tarieven.nza.nl/Nzatarieven/top.do〉 (2012). Accessed August 2012.
36. Glassman, S.D., Polly, D.W., Dimar, J.R. & Carreon, L.y. The cost efectiveness of single-level instrumented posterolateral lumbar fusion at 5 years after surgery. Spine 37, 769-774 (2012).